ALITHIOS Phase IIIb open-label extension study data based on ~3.5 years of exposure demonstrated that mean immunoglobulin G (IgG) levels in patients treated with Kesimpta…
Regulatory decisions for Beovu (brolucizumab) in diabetic macular edema (DME) are expected in mid-2022 in the US and Europe DME is the leading cause of…
MS PATHS data indicate that 100 percent of people with MS treated with natalizumab, interferons or fumarates achieved an antibody response following COVID-19 vaccination Data from this…
If approved by the FDA, maribavir will be the first and only treatment indicated for adults in this patient population CMV is one of the…
Takeda Pharmaceutical Company Limited today announced that a safety signal has emerged in Phase 2 studies of TAK-994, an investigational oral orexin agonist. As an…
Merck, known as MSD outside the United States and Canada, in collaboration with the bone cancer advocacy community and Emmy- nominated actress, Yvonne Orji, launched…
Acquisition Complements and Strengthens Merck’s Cardiovascular Pipeline Sotatercept is a Potentially First-In-Class Therapy in Phase 3 Development for the Treatment of Pulmonary Arterial Hypertension REBLOZYL ® (luspatercept-aamt)…
Phase IV LEADER-75 study showed 25 percent reduction in standard dose of gadobutrol is non-inferior to gadoterate full dose in improvement of visualization imaging parameters…
The ‘Your Right to Plan’ campaign aims at improving family planning and reproductive health services to Egypt’s underserved communities / The five-year partnership involves a…
In an updated analysis on the adult subset of non-central systema nervosum (CNS) / TRK fusion cancer patients from three larotrectinib clinical trials, a high…
Andes has developed novel seed treatment technology that allows crops to thrive without synthetic fertilizers / Funds will aid the development of revolutionary nature-based carbon…
Updated analyses for Vitrakvi™ (larotrectinib) reaffirm sustained clinical benefits for patients with TRK fusion cancer / Breadth of prostatic adenocarcinoma portfolio on display, including presentations…